EMERYVILLE, Calif., Nov. 18 /PRNewswire/ -- KineMed, Inc., a platform- based drug development and advanced medical diagnostics company, presented results at 11:50 AM (PST) today from their insulin resistance program at the 3rd Annual World Congress on the Insulin Resistance Syndrome held in San Francisco from November 17th-19th.
As part of the session entitled “Recent Developments in Identifying Patients with Insulin Resistance,” the Company presented data from a study describing and validating the insulin resistance test (the deuterated glucose disposal test or 2H-GDT), including comparison with the traditional hyperinsulinemic-euglycemic glucose clamp method. The 2H-GDT was first demonstrated to detect insulin resistance in animal models due to both genetic and dietary factors, and to quantify the insulin sensitizing response to drugs (rosiglitazone and metformin). Data on beta-cell compensation to insulin resistance is also provided by this test, and differences were detected between strains of animals. Next, a study was performed in lean individuals and subjects with Metabolic Syndrome to demonstrate the reliability of the assay in measuring insulin resistance in humans. Measurements taken in 17 subjects showed a remarkably close correlation between the KineMarker(TM) and clamp data (R = 0.95) and documented insulin resistance in Metabolic Syndrome. The company also presented data quantifying the presence and degree of insulin resistance in a survey of lean and overweight subjects.
David Fineman, President and CEO of KineMed, commented, “This technology provides drug developers and clinicians a clinically feasible method of measuring insulin resistance which is, importantly, highly correlated with the labor intensive, expensive and impractical hyperinsulinemic-euglycemic glucose clamp method. KineMed’s insulin resistance KineMarker(TM) characterizes glucose homeostatic status and susceptibility to developing type 2 diabetes. Our results show that KineMed’s KineMarker allows pancreatic compensation to be measured at the same time that the degree of insulin resistance is measured. Applications include development of new drugs targeting pre- diabetes, diabetes and the metabolic syndrome.”
KineMed KineMarker(TM) Product Programs in Diabetes
KineMed’s proprietary in vivo KineMarker(TM) assays provide new, sensitive and high-throughput measures of several key metabolic pathways involved in the pathogenesis and treatment of diabetes and other metabolic disorders. These assays can be used in clinical as well as pre-clinical settings.
KineMed’s insulin resistance KineMarker(TM) is much easier to apply and less labor-intensive than the traditional hyperinsulinemic-euglycemic glucose clamp method, which is the current “gold-standard” in the field. Clinical trial efficiency and patient comfort are thereby improved considerably. Subjects drink a specially labeled glucose-containing drink, and two blood draws over a three hour period.
KineMed’s second product program in diabetes offers a pre-clinical measure of pancreatic beta-cell proliferation. This assay provides a new, less labor- intensive, more sensitive and much more highly reproducible measure of insulin-secreting cell (pancreatic beta-cell) regeneration in pre-clinical models. New drug candidates that target the regeneration of pancreatic beta- cells are being developed, but previous methods could only measure pancreatic beta-cell mass by histology rather than the true regeneration rate of beta- cells, as KineMed’s test achieves.
About KineMed, Inc.
KineMed, Inc. provides a proprietary set of tools for measuring the dynamics of molecular and cellular response to drugs in the intact organism, both in animals and humans. KineMed’s technology is ideally suited to enable the discovery of entirely new, unanticipated uses for compounds (an approach called repurposing or repositioning) by screening for activity in vivo across a wide variety of disease states. The breadth of therapeutic targets covered by KineMarker(TM) assays allows high-throughput screening in conditions beyond those typically evaluated. KineMed’s technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.
For further information about KineMed, please visit: http://www.kinemed.com/ .
KineMed, Inc.
CONTACT: Lisa Misell, Ph.D., Director of Business Development of KineMed,+1-510-655-6525, ext. 117; or Media: Justin Jackson, Burns McClellan,+1-212-213-0006, jjackson@burnsmc.com, for KineMed, Inc.
Web site: http://www.kinemed.com/
